A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Trial Profile

A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Procedural pain
  • Focus Therapeutic Use
  • Sponsors Juniper Pharmaceuticals
  • Most Recent Events

    • 17 Aug 2016 Primary endpoint has not been met "Pain Intensity recorded on the 11-point NPRS" according to a Juniper Pharmaceuticals media release.
    • 17 Aug 2016 According to a Juniper Pharmaceuticals media release, the development of COL-1077 was discontinued based on the results of this study.
    • 04 Aug 2016 According to a Juniper Pharmaceuticals media release, the company anticipates to report top-line results from this trial by Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top